MedTrace Logo

ADDIA Chronobiological Study

NCT02973971 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2024-09-19

No results posted yet for this study

Summary

The present single center clinical chronobiological study on 24 subjects (12 patients with mild to moderate form of Alzheimer's disease and 12 Healthy subjects) aims at characterizing the ADDIA biomarkers: a) blood cell-based biomarkers measured by flow cytometry using proprietary probes specific of two targeted biomarkers, beta-Amyloid (Aβ) peptide and a kinase, and b) circulating biomarkers in peripheral body fluids. The biomarkers will be analyzed on samples taken at different time points of the day, including under fasting and non-fasting conditions and at two periods: day 1 and day 14.

Conditions

  • Alzheimer Disease

Interventions

OTHER

volumeric MRI

Sponsors & Collaborators

  • Amoneta Diagnostics SAS

    lead INDUSTRY

Principal Investigators

  • Frédéric Blanc, MD · Hôpitaux Strasbourg

  • Catherine Mutter, MD · Hôpitaux Strasbourg

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-03-29
Completion
2018-03-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02973971 on ClinicalTrials.gov